Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson. Chief Executive Officer Ying Huang said Legend is the “world’s largest standalone cell therapy company” and described CARVYKTI [...]
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use
